The Successful Complete Remission Induction by Sorafenib Monotherapy in a FLT3-D835Y-Positive Patient with Refractory Acute Monocytic Leukemia.

about

The Successful Complete Remission Induction by Sorafenib Monotherapy in a FLT3-D835Y-Positive Patient with Refractory Acute Monocytic Leukemia.

Item

http://www.wikidata.org/entity/Q41816386

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

The Successful Complete Remiss ...... tory Acute Monocytic Leukemia.

@en

type

Item

label

The Successful Complete Remiss ...... tory Acute Monocytic Leukemia.

@en

prefLabel

The Successful Complete Remiss ...... tory Acute Monocytic Leukemia.

@en

P1476

The Successful Complete Remiss ...... tory Acute Monocytic Leukemia.

@en

P2093

Depei Wu

http://www.w3.org/2001/XMLSchema#string

Hongjie Shen

http://www.w3.org/2001/XMLSchema#string

Jin Zhou

http://www.w3.org/2001/XMLSchema#string

Liang Ma

http://www.w3.org/2001/XMLSchema#string

Miao Miao

http://www.w3.org/2001/XMLSchema#string

Song Jin

http://www.w3.org/2001/XMLSchema#string

Suning Chen

http://www.w3.org/2001/XMLSchema#string

Ting Xu

http://www.w3.org/2001/XMLSchema#string

P2860

Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.

Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.

Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia

Sorafenib is tolerable and improves clinical outcomes in patients with FLT3-ITD acute myeloid leukemia prior to stem cell transplant and after relapse post-transplant

Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.

FLT3: ITDoes matter in leukemia.

Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia.

P2888

s12288-015-0586-2

P304

38-40

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.1007/S12288-015-0586-2

http://www.w3.org/2001/XMLSchema#string

P433

Suppl 1

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Yanhua Yue

P577

2015-08-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1007811366

http://www.w3.org/2001/XMLSchema#string

P698

27408351

http://www.w3.org/2001/XMLSchema#string

P932

4925519

http://www.w3.org/2001/XMLSchema#string